Okyo Pharma (OKYO) pipeline
TrialRedline tracks 3 clinical trials sponsored by Okyo Pharma Ltd: 1 Phase 3, 2 Phase 2.
Company identity checked against sources
Which trial dates moved later?
Okyo Pharma clinical trials we track
Check company identity sourcePhase 3 1 trial
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).NCT07838506 | Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks. | Not yet recruiting | 2027-05Estimated |
Phase 2 2 trials
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye DiseaseNCT05759208 | OK-101 | Completed | 2023-12-15Actual |
| The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal PainNCT06637527 | OK-101 0.05%, OK-101 0.1% | Terminated | 2025-04-30Actual |
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
Trial details
- Registry ID
- NCT05759208
- Drugs studied
- OK-101
The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
Trial details
- Registry ID
- NCT06637527
- Drugs studied
- OK-101 0.05%, OK-101 0.1%
Drugs in these trials
Names as written in the registry records.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: The change from baseline at Week 12 in ocular pain assessed by VAS score. Description: Evaluate the efficacy and safety of urcosimod 0.05% as compared to placebo instilled 4 times/day in participants who have a documented ocular history of symptoms of neuropathic corneal pain. Time frame: From baseline (time of randomization) compared to Week 12.. After: Measure: The change from baseline at Week 12 in ocular pain assessed by Visual Analogue Scale (0-10) score. (Score of 10 is "worst possible pain".) Description: Evaluate the efficacy and safety of urcosimod 0.05% as compared to placebo instilled 4 times/day in participants who have a documented ocular history of symptoms of neuropathic corneal pain. Time frame: From baseline (time of randomization) compared to Week 12..